UCB SA - BNP Paribas Fortis

3 These Directors are representatives of Financière de Tubize S.A., the reference shareholder of the
Issuer
The business address for each of the foregoing Directors is UCB S.A., 60 Allée de la Recherche, 1070
Brussels, Belgium.
Karel Boone was appointed chairman of the Board in 2008, after being appointed to the Board in 2000.
A commercial engineer (K.U.Leuven, Belgium), Karel Boone started in 1966 as an executive member
of the board of directors of Lotus Bakeries S.A. (now Lotus Biscuits S.A.) and became chief executive
officer in 1974 when Lotus Biscuits merged with Corona. He was also Executive Chairman of the
Board of Directors from 1992 until 2006 when he became non-Executive Chairman of the Board. He is
a member of the following boards of directors: Axa Belgium S.A., Banque Degroof S.A., Compagnie
du Bois Sauvage S.A. and Vendemoortele S.A. (chairman). He is a member of the Corporate
Governance Committee for Belgian listed companies. He is also active in professional organisations; he
has been chairman of the Federation of Belgian Companies.
Evelyn du Monceau has been a member of the Board since 1984 and has been elected vice-chairperson
of the Board since 2006. She has also acted as chairperson of the Remuneration and Nominations
Committee since 2006. Evelyn du Monceau graduated in Applied Economics from the Catholic
University of Louvain UCL in Belgium. She then followed courses in International Relations at the
Kennedy School of Harvard University (U.S.) and in Soil Science, Animal Science and Zoology at the
Agricultural and Technical College of Farmingdale (U.S.). Evelyn du Monceau is a member of the
board of directors of Financière de Tubize S.A. and of Solvac S.A.
Roch Doliveux is a doctor in Veterinarian Medicine from Maisons-Alfort (France), and also Laureate of
the Faculty of Medicine, Créteil, and holds an MBA from INSEAD (France) with distinction. He joined
the pharmaceutical industry early, first at Ciba-Geigy (now Novartis) in Switzerland, in Peru and in
France, and then at Schering-Plough Corporation in various positions, including President of Schering-
Plough International. Then, Roch Doliveux joined the Pierre Fabre group a Chief Executive Officer of
Pierre Fabre Pharmaceuticals. Roch Doliveux joined UCB in October 2003 as Director General of the
Pharma Sector and Deputy Chairman of the Executive Committee. He became CEO and Chairman of
the Executive Committee of UCB Group on January 1, 2005. He is a member of the Board of Directors
of UCB, as well as a member of the Board of the European Federation of Pharmaceutical Association
(EFPIA), of the INSEAD International Council, the Science & Business Innovation Board, the Caring
Entrepreneurship Fund (King Baudouin Foundation) and WILL (Walloon Institute for Life Lead
Sciences).
Prince Lorenz of Belgium was appointed to the Board in 2001. Prince Lorenz of Belgium has studied
economics in Switzerland and Austria. After one and a half years spent in various banks in London,
Paris and Rome, he started a career in 1983 at E. Gutzwiller & Cie, Banquiers in Basle and later became
the company’s managing partner, a position he continues to hold. In 1993, he spent one year as
Consultant for Swift S.C.CEO and from 1995 he became an advisor to the board of directors of BNP
Paribas in Paris. He is a member of various boards of directors in Europe.
Armand de Decker has been a member of the Board of the Issuer since 2008. Armand de Decker holds
a Master of Law Degree from the University of Brussels (ULB, Belgium) and started his career as a
lawyer. In parallel, from 1979, he pursued a political career within the Belgian Liberal Party. In 1981,
he was elected to the Belgian Chamber of Representatives where he served until 1995. In 1995, he was
elected to the Belgian Senate, and re-elected in 1999, 2003 and 2007. He served as President of the
Council of the Brussels-Capital Region from 1995 to 1999, and from 1999 to 2004 he was President of
the Senate. From 20 July 2004 until 12 July 2007, he served as the Minister of International
A11250830/2.25/23 Oct 2009 93